Pulmotect

Pulmotect Inc., founded in Houston, focuses on developing innovative biotechnology solutions to enhance immune responses against lung infections. The company's core mission is to harness the power of the innate immune system to provide immediate and effective protection against respiratory pathogens. Pulmotect's lead product, PUL-, is an inhaled therapeutic currently in clinical stages, designed to stimulate the immune system in the lungs to combat viral, bacterial, and fungal infections. The company targets healthcare markets needing advanced treatments for respiratory conditions.

Pulmotect has garnered attention through its successful Phase I/2a clinical trials, which demonstrated that PUL- was well tolerated in both healthy individuals and those with COPD. The company has also shown promising results in exploratory phase trials, indicating anti-viral activity and clinical efficacy. Supported by a team of experts in immunology and respiratory diseases, Pulmotect's advancements have the potential to significantly impact public health by providing new therapeutic options for lung infections.